Suppr超能文献

血清铁蛋白测量的协调状态及其作为铁相关疾病标志物的应用意义。

Harmonization Status of Serum Ferritin Measurements and Implications for Use as Marker of Iron-Related Disorders.

机构信息

Research Centre for Metrological Traceability in Laboratory Medicine (CIRME), Università degli Studi di Milano, Milan, Italy.

出版信息

Clin Chem. 2022 Sep 1;68(9):1202-1210. doi: 10.1093/clinchem/hvac099.

Abstract

BACKGROUND

Serum ferritin is considered a suitable biomarker of iron-related disorders. However, data about the comparability of results among commercial measuring systems (MSs) are contradictory. We performed an intercomparison study aimed at verifying the current interassay variability and its impact on clinical application of the test. Obtaining this information is vital because manufacturers continue to claim calibration alignment to different WHO preparations, which are not related to each other in terms of traceability.

METHODS

Four widely used MSs were evaluated. The interassay agreement was verified using 39 human serum pools. The recovery of WHO International Standard (IS) 94/572 (the only reference material available at the time of the study) was evaluated, after assessing the material commutability. Finally, an approach for harmonizing ferritin results was proposed.

RESULTS

Highly significant differences (P < 0.00001) among ferritin concentrations assayed by different MSs were detected and the interassay CV (median 22.9%; interquartile range 21.8-25.5) overlapped the desirable intermethod bias (24.6%). IS 94/572 was commutable for use only with Access and Centaur, with Access being the only MS correctly recovering its assigned value. Accordingly, we used regression data against Access to recalibrate MSs, indirectly aligning them to IS 94/572, with a substantial improvement in degree of harmonization and traceability to higher-order reference.

CONCLUSIONS

The harmonization among evaluated ferritin MSs is far from optimal, with the implementation of traceability to different WHO ISs being a factor of confusion. A recalibration approach, however, would permit measurement harmonization, allowing the use of common decision thresholds.

摘要

背景

血清铁蛋白被认为是与铁相关疾病的合适生物标志物。然而,关于商业测量系统(MS)之间结果可比性的数据存在矛盾。我们进行了一项相互比较的研究,旨在验证当前的实验内变异性及其对测试临床应用的影响。获得这些信息至关重要,因为制造商继续声称校准与不同的世卫组织制剂对齐,而这些制剂在可追溯性方面彼此没有关联。

方法

评估了四个广泛使用的 MS。使用 39 个人血清池验证了实验内一致性。在评估材料可互换性后,评估了世界卫生组织国际标准(IS)94/572(研究时唯一可用的参考物质)的回收率。最后,提出了一种协调铁蛋白结果的方法。

结果

不同 MS 检测的铁蛋白浓度之间存在非常显著的差异(P < 0.00001),实验内 CV(中位数 22.9%;四分位距 21.8-25.5)与理想的实验内偏差(24.6%)重叠。IS 94/572 仅与 Access 和 Centaur 可互换使用,只有 Access 是唯一正确回收其指定值的 MS。因此,我们使用与 Access 的回归数据来重新校准 MS,间接将其与 IS 94/572 对齐,从而大大提高了协调程度和向更高阶参考的可追溯性。

结论

评估的铁蛋白 MS 之间的协调远非最佳,实施与不同世卫组织 IS 的可追溯性是一个混乱的因素。然而,重新校准方法将允许测量协调,从而使用共同的决策阈值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验